Cargando…

The 150 most important questions in cancer research and clinical oncology series: questions 94–101: Edited by Cancer Communications

Since the beginning of 2017, Cancer Communications (former title: Chinese Journal of Cancer) has published a series of important questions regarding cancer research and clinical oncology, to provide an enhanced stimulus for cancer research, and to accelerate collaborations between institutions and i...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257962/
https://www.ncbi.nlm.nih.gov/pubmed/30477575
http://dx.doi.org/10.1186/s40880-018-0341-9
_version_ 1783374431134941184
collection PubMed
description Since the beginning of 2017, Cancer Communications (former title: Chinese Journal of Cancer) has published a series of important questions regarding cancer research and clinical oncology, to provide an enhanced stimulus for cancer research, and to accelerate collaborations between institutions and investigators. In this edition, the following 8 valuable questions are presented. Question 94. The origin of tumors: time for a new paradigm? Question 95. How can we accelerate the identification of biomarkers for the early detection of pancreatic ductal adenocarcinoma? Question 96. Can we improve the treatment outcomes of metastatic pancreatic ductal adenocarcinoma through precision medicine guided by a combination of the genetic and proteomic information of the tumor? Question 97. What are the parameters that determine a competent immune system that gives a complete response to cancers after immune induction? Question 98. Is high local concentration of metformin essential for its anti-cancer activity? Question 99. How can we monitor the emergence of cancer cells anywhere in the body through plasma testing? Question 100. Can phytochemicals be more specific and efficient at targeting P-glycoproteins to overcome multi-drug resistance in cancer cells? Question 101. Is cell migration a selectable trait in the natural evolution of carcinoma?
format Online
Article
Text
id pubmed-6257962
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62579622018-11-30 The 150 most important questions in cancer research and clinical oncology series: questions 94–101: Edited by Cancer Communications Cancer Commun (Lond) Editorial Since the beginning of 2017, Cancer Communications (former title: Chinese Journal of Cancer) has published a series of important questions regarding cancer research and clinical oncology, to provide an enhanced stimulus for cancer research, and to accelerate collaborations between institutions and investigators. In this edition, the following 8 valuable questions are presented. Question 94. The origin of tumors: time for a new paradigm? Question 95. How can we accelerate the identification of biomarkers for the early detection of pancreatic ductal adenocarcinoma? Question 96. Can we improve the treatment outcomes of metastatic pancreatic ductal adenocarcinoma through precision medicine guided by a combination of the genetic and proteomic information of the tumor? Question 97. What are the parameters that determine a competent immune system that gives a complete response to cancers after immune induction? Question 98. Is high local concentration of metformin essential for its anti-cancer activity? Question 99. How can we monitor the emergence of cancer cells anywhere in the body through plasma testing? Question 100. Can phytochemicals be more specific and efficient at targeting P-glycoproteins to overcome multi-drug resistance in cancer cells? Question 101. Is cell migration a selectable trait in the natural evolution of carcinoma? BioMed Central 2018-11-26 /pmc/articles/PMC6257962/ /pubmed/30477575 http://dx.doi.org/10.1186/s40880-018-0341-9 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Editorial
The 150 most important questions in cancer research and clinical oncology series: questions 94–101: Edited by Cancer Communications
title The 150 most important questions in cancer research and clinical oncology series: questions 94–101: Edited by Cancer Communications
title_full The 150 most important questions in cancer research and clinical oncology series: questions 94–101: Edited by Cancer Communications
title_fullStr The 150 most important questions in cancer research and clinical oncology series: questions 94–101: Edited by Cancer Communications
title_full_unstemmed The 150 most important questions in cancer research and clinical oncology series: questions 94–101: Edited by Cancer Communications
title_short The 150 most important questions in cancer research and clinical oncology series: questions 94–101: Edited by Cancer Communications
title_sort 150 most important questions in cancer research and clinical oncology series: questions 94–101: edited by cancer communications
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257962/
https://www.ncbi.nlm.nih.gov/pubmed/30477575
http://dx.doi.org/10.1186/s40880-018-0341-9
work_keys_str_mv AT the150mostimportantquestionsincancerresearchandclinicaloncologyseriesquestions94101editedbycancercommunications
AT 150mostimportantquestionsincancerresearchandclinicaloncologyseriesquestions94101editedbycancercommunications